Starlake Bioscience Co Inc Zhaoqing Guangdong Total Liabilities
Starlake Bioscience Co Inc Zhaoqing Guangdong total liabilities. Based on the latest financial reports, Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) has total liabilities worth CN¥8.99 Billion CNY (≈ $1.32 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Starlake Bioscience Co Inc Zhaoqing Guan asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Starlake Bioscience Co Inc Zhaoqing Guangdong (1994–2025)
Total liabilities of Starlake Bioscience Co Inc Zhaoqing Guangdong from 1994 to 2025. This chart illustrates how Starlake Bioscience Co Inc Zhaoqing Guangdong's total liabilities have evolved over time, based on quarterly financial data. Explore Starlake Bioscience Co Inc Zhaoqing Guan (600866) investment intensity to see how much of total assets are deployed in long-term investments.
Starlake Bioscience Co Inc Zhaoqing Guangdong Competitors by Total Liabilities
The table below lists competitors of Starlake Bioscience Co Inc Zhaoqing Guangdong ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Cuiwei Tower Co Ltd
SHG:603123
|
China | CN¥4.51 Billion |
|
SPG Co. Ltd
KQ:058610
|
Korea | ₩170.49 Billion |
|
Burke & Herbert Financial Services Corp. Common Stock
NASDAQ:BHRB
|
USA | $7.07 Billion |
|
NationGate Holdings Berhad
KLSE:0270
|
Malaysia | RM1.30 Billion |
|
Altareit
PA:AREIT
|
France | €2.67 Billion |
|
Capitol Federal Financial Inc
NASDAQ:CFFN
|
USA | $8.64 Billion |
|
Helix Energy Solutions Group Inc
NYSE:HLX
|
USA | $1.06 Billion |
|
TotalEnergies EP Gabon S.A.
PA:EC
|
France | €1.30 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Starlake Bioscience Co Inc Zhaoqing Guangdong's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Starlake Bioscience Co Inc Zhaoqing Guan assets under control.
Liquidity & Leverage Metrics
Starlake Bioscience Co Inc Zhaoqing Guangdong Total Liabilities Ratios Explained
Starlake Bioscience Co Inc Zhaoqing Guangdong total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Starlake Bioscience Co Inc Zhaoqing Guangdong's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Starlake Bioscience Co Inc Zhaoqing Guangdong (1994–2025)
The table below shows the annual total liabilities of Starlake Bioscience Co Inc Zhaoqing Guangdong from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥8.79 Billion ≈ $1.29 Billion |
+34.83% |
| 2024-12-31 | CN¥6.52 Billion ≈ $953.84 Million |
-3.08% |
| 2023-12-31 | CN¥6.73 Billion ≈ $984.11 Million |
-25.85% |
| 2022-12-31 | CN¥9.07 Billion ≈ $1.33 Billion |
+1199.80% |
| 2021-12-31 | CN¥697.74 Million ≈ $102.10 Million |
-7.34% |
| 2020-12-31 | CN¥752.97 Million ≈ $110.18 Million |
+26.35% |
| 2019-12-31 | CN¥595.95 Million ≈ $87.21 Million |
+21.89% |
| 2018-12-31 | CN¥488.94 Million ≈ $71.55 Million |
-8.54% |
| 2017-12-31 | CN¥534.57 Million ≈ $78.22 Million |
-16.20% |
| 2016-12-31 | CN¥637.90 Million ≈ $93.35 Million |
-19.85% |
| 2015-12-31 | CN¥795.88 Million ≈ $116.46 Million |
+1.08% |
| 2014-12-31 | CN¥787.37 Million ≈ $115.22 Million |
-30.83% |
| 2013-12-31 | CN¥1.14 Billion ≈ $166.57 Million |
-32.96% |
| 2012-12-31 | CN¥1.70 Billion ≈ $248.48 Million |
+4.80% |
| 2011-12-31 | CN¥1.62 Billion ≈ $237.09 Million |
+132.10% |
| 2010-12-31 | CN¥698.07 Million ≈ $102.15 Million |
+46.24% |
| 2009-12-31 | CN¥477.36 Million ≈ $69.85 Million |
-17.76% |
| 2008-12-31 | CN¥580.44 Million ≈ $84.94 Million |
-4.42% |
| 2007-12-31 | CN¥607.29 Million ≈ $88.87 Million |
+17.49% |
| 2006-12-31 | CN¥516.89 Million ≈ $75.64 Million |
+5.58% |
| 2005-12-31 | CN¥489.57 Million ≈ $71.64 Million |
+19.16% |
| 2004-12-31 | CN¥410.86 Million ≈ $60.12 Million |
+53.99% |
| 2003-12-31 | CN¥266.82 Million ≈ $39.04 Million |
+41.26% |
| 2002-12-31 | CN¥188.89 Million ≈ $27.64 Million |
-23.21% |
| 2001-12-31 | CN¥245.97 Million ≈ $35.99 Million |
-25.81% |
| 2000-12-31 | CN¥331.53 Million ≈ $48.51 Million |
+130.43% |
| 1999-12-31 | CN¥143.87 Million ≈ $21.05 Million |
-13.09% |
| 1998-12-31 | CN¥165.54 Million ≈ $24.22 Million |
+53.52% |
| 1997-12-31 | CN¥107.83 Million ≈ $15.78 Million |
-37.62% |
| 1996-12-31 | CN¥172.86 Million ≈ $25.30 Million |
-7.81% |
| 1995-12-31 | CN¥187.51 Million ≈ $27.44 Million |
+21.64% |
| 1994-12-31 | CN¥154.15 Million ≈ $22.56 Million |
-- |
About Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and selling food additives, feed additives, pharmaceutical intermediates, active pharmaceutical ingredients, organic fertilizers, and bio-based new materials. It operates through three main business lines: food and feed additives, biochemical raw materials and pharmaceutical intermediates, and organic fertilizers. The com… Read more